This is a million-dollar question for the many patients who have received PARP inhibitors for maintenance therapy, followed by platinum-based chemotherapy for a recurrence. Several studies are underway, investigating whether PARP inhibitors can be effective when used again. Some clinicians have begun to use PARP after PARP, while acknowledging the limitations of our understanding